Jinghua Pharmaceutical Group (002349.SZ): Jidesheng Snake Medicine Tablets receives drug clinical trial approval for new herpes zoster indication
Jinghua Pharmaceutical (002349.SZ) announced that recently, the company received the "Drug Clinical Trial Approval Notice" (Acceptance Number: CXZL2600062; Notice Number: 2026LP03037) approved and issued by the National Medical Products Administration. The company's Jidesheng Snake Medicine Tablets' clinical trial application for adding a new indication for herpes zoster (liver-gallbladder damp-heat syndrome) has been approved. Jidesheng Snake Medicine Tablets is an existing marketed product of the company. This approval pertains to the approval of a clinical trial application for adding a new indication to a marketed traditional Chinese medicine product, and will not have a significant impact on the company's current operating performance.
Jinghua Pharmaceutical Group (002349.SZ) announced that recently, the company received the "Drug Clinical Trial Approval Notice" (Acceptance No.: CXZL2600062; Notice No.: 2026LP03037) approved and issued by the National Medical Products Administration. The company's Jidesheng Snake Medicine Tablets application for clinical trials to add a new indication for herpes zoster (liver-gallbladder damp-heat syndrome) has been approved. Jidesheng Snake Medicine Tablets is an existing marketed product of the company. This approval pertains to the approval of a clinical trial application for adding a new indication to a marketed traditional Chinese medicine product, and will not have a material impact on the company's current operating performance.
Related Articles
ST HLDGS (08305) Enters into Procurement Cooperation Agreement with Letian Investment to Jointly Build a Supply Chain Business Operations Platform
Policy package stabilizes expectations; institutions: the foundation for the market's medium- to long-term uptrend remains unchanged.
INT MEDICAL (01501): Proposes to issue no more than 37,270,600 A shares in total.
ST HLDGS (08305) Enters into Procurement Cooperation Agreement with Letian Investment to Jointly Build a Supply Chain Business Operations Platform
Policy package stabilizes expectations; institutions: the foundation for the market's medium- to long-term uptrend remains unchanged.
INT MEDICAL (01501): Proposes to issue no more than 37,270,600 A shares in total.
